This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-4 (Cancelled)

5. (Withdrawn) Use according to claim 2 wherein the CD137-specific antisense expression vector is RSV-ILA-AS.

6. (Withdrawn) Use according to claim 1 wherein the CD137 antagonist is selected from the group consisting of a CD137 ligand-specific antibody, peptide, organic small molecule, antisense oligonucleotide, siRNA, antisense expression vector or recombinant virus.

7. -8 (Cancelled)

9.(Currently amended) A method ~~Method~~ of treating a CD137 expressing tumor in a patient comprising administering to a patient in need thereof an effective amount of a CD137 antagonist.

10.(Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is ~~selected from the group consisting of~~ a CD137-specific antibody, a peptide, an organic small molecule, an antisense oligonuclotide, a siRNA, an antisense expression vector or a recombinant virus.

11. (Currently Amended) A method ~~Method~~ according to claim 9 wherein the tumor is a B cell lymphoma, a tumor of the vulva, a nephroblastoma, a cystadenocarcinoma of the ovary, a rhabdomysarcoma, a leiomyosarcoma, a fibrosarcoma, an immunocytoma, a non-Hodgkin lymphoma, a carcinoma of the portio uteri or a basal cell carcinoma.

12.(Currently amended) A method ~~Method~~ according to claim 11 wherein the B

cell lymphoma is chronic lymphocytic leukemia ~~leukaemia~~.

13 (Withdrawn-Currently Amended) ~~Use of CD137 or a functional analogue or derivative thereof for the preparation of a medicament~~ A method for the treatment of ~~conditions~~ a condition characterised by undesired or overactive immune responses comprising administering to a patient having a condition characterised by undesired or overactive immune response a therapeutically effective amount of a medicament comprising CD137 or a functional analogue or derivative thereof.

14. (Withdrawn-Currently Amended) ~~Use~~ A method according to claim 13 wherein the CD137 or functional analogue or derivative is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in ~~Fig. 8A~~ SEQ. ID No. 1.

15.(Withdrawn-Currently amended) ~~Use~~ A method according to claim 14 wherein the CD137 has the amino acid sequence shown in ~~Fig. 8B~~ SEQ. ID No. 2.

16.(Withdrawn-Currently Amended) ~~Use~~ A method according to claim 13 wherein the condition is ~~selected from~~ an autoimmune disease, an allergy,~~diseases, allergies,~~ asthma ~~and~~ or an organ transplant rejection.

17. (Withdrawn-Currently Amended) ~~Use~~ A method ~~of an agonistic anti-CD137 ligand antibody~~ for the preparation of a medicament for the treatment of ~~conditions~~ a condition characterised by an undesired or overactive immune response ~~responses~~ comprising admixing an agonistic anti-CD137 ligand antibody with a pharmaceutically acceptable carrier.

18.(Withdrawn-Currently Amended) ~~Use~~ A method according to claim 17 wherein the condition is ~~selected from autoimmune diseases, allergies, asthma and organ transplant rejection~~ an autoimmune disease, an allergy, asthma or an organ transplant rejection.

19. (Withdrawn-Currently Amended) A method ~~Method~~ for treating a patient suffering from a condition characterised by an undesired or overactive immune ~~responses~~ response comprising administering an effective amount of CD137 or a functional analogue or derivative thereof and/or an agonistic anti-CD137 ligand antibody.

20.(Withdrawn-Currently Amended) A method ~~Method~~ of claim 19 wherein the CD137 or functional analogue or derivative thereof is encoded by a nucleic acid comprising a nucleotide sequence having at least 90% homology to the coding sequence shown in ~~Fig. 8A~~ SEQ. ID No. 1.

21.(Withdrawn-Currently Amended) A method ~~Method~~ of claim 19 wherein the condition is ~~selected from~~ an autoimmune disease ~~diseases~~, an allergy ~~allergies~~, asthma ~~and~~ or an organ transplant rejection.

22.(Currently amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is an antibody directed to at least one epitope of the amino acid sequence of human CD137 shown in ~~Fig. 8B~~ SEQ. ID No. 2.

23.(Currently amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is clone BBK- 2 or clone 4B4-1

24.(Withdrawn-Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is the antisense expression vector RSV-ILA-AS.

25.(Withdrawn-Currently Amended) A method ~~Method~~ according to claim 9 wherein the CD137 antagonist is ~~selected from the group consisting of~~ a CD137 ligand-specific

antibody, a peptide, an organic small molecule, an antisense oligonucleotide, a siRNA, an antisense expression vector or a recombinant virus.

26.(Withdrawn-Currently Amended) A method ~~Method~~ of claim 20 wherein the CD137 has the amino acid sequence shown in ~~Fig. 8B~~ SEQ. ID No. 2.